PHARMACOKINETICS OF AMOXICILLIN DURING PREGNANCY AND POSTPARTUM

阿莫西林在妊娠期和产后的药代动力学

• 批准号: 7379324
• 负责人: MARY F HEBERT
• 金额: $ 0.99万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379324
• 关键词: PHARMACOKINETICS; AMOXICILLIN; DURING; PREGNANCY; POSTPARTUM

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pregnant women are considered an "orphan" population for drug development. Even for drugs commonly administered to pregnant women, such as amoxicillin, there is very limited information available on the pharmacokinetics (PK) of the drug during pregnancy as compared to postpartum. During the recent anthrax scare in Washington DC, there were many individuals exposed or potentially exposed to anthrax spores who received antibiotic prophylaxis. Some of these individuals were pregnant. Because of the lack of information on the PK of amoxicillin during pregnancy and the expected increased elimination of drugs (such as amoxicillin) eliminated by the kidneys during pregnancy, physicians can only guess at the appropriate dose to use. The purpose of this study is to evaluate the pharmacokinetics of amoxicillin during pregnancy and postpartum. We will give healthy pregnant women a single oral dose of amoxicillin (500 mg) during the second (18-22 weeks gestation) and third (30-34 weeks gestation) trimesters of pregnancy and 3 months postpartum. Blood and urine samples will be collected throughout the study days. Healthy pregnant women prior to 18 weeks gestation will be recruited for this study.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。孕妇被认为是用于药物开发的“孤儿”人群。即使对于通常针对孕妇服用的药物，例如阿莫西林，与产后相比，怀孕期间有关药物的药代动力学（PK）的信息非常有限。在最近在华盛顿特区的炭疽恐慌中，有许多人暴露于接受抗生素预防的炭疽孢子。其中一些人怀孕了。由于怀孕期间缺乏有关阿莫西林PK的信息，并且预计在怀孕期间肾脏消除的药物消除（例如阿莫西林）会增加​​，因此医生只能猜测适当的剂量要使用。这项研究的目的是评估怀孕和产后阿莫西林的药代动力学。我们将在第二次（18-22周妊娠）和第三次（30-34周妊娠）怀孕和产后3个月的三个月（30-34周妊娠期）中给健康的孕妇单一口服阿莫西林（500 mg）（500 mg）。在整个研究期间，将收集血液和尿液样本。这项研究将在18周之前妊娠18周之前妊娠。